Drug Database
Back to search

Netherlands· NL-20033cb77763

Triumeq 5 mg/ 60 mg/ 30 mg dispergeerbare tabletten

A lamivudine, abacavir and dolutegravir product containing abacavirsulfaat + dolutegravir natrium + lamivudine 0-water, registered in Netherlands by ViiV Healthcare B.V.. The same ATC class is registered in 13 of our 19 countries.

ATC J05AR13

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedTriumeq 5 mg/ 60 mg/ 30 mg dispergeer…ATCJ05AR13REGISTER NO.NL-20033cb77763PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about abacavirsulfaat + dolutegravir natrium + lamivudine 0-waterAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lamivudine, abacavir and dolutegravir is registered in 13 of 19 countries.

Countries holding a registration under ATC J05AR13 (lamivudine, abacavir and dolutegravir), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose
Search lamivudine, abacavir and dolutegravir products by name

Lamivudine, abacavir and dolutegravir · ATC J05AR13

13 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
ABACAVIRSULFAAT + DOLUTEGRAVIR NATRIUM + LAMIVUDINE 0-WATER
Manufacturer
ViiV Healthcare B.V.
Country
Netherlands (NL)
ATC code
J05AR13
ATC class
Lamivudine, abacavir and dolutegravir
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/14/940

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

2 interactions on record for lamivudine, abacavir and dolutegravir.

Mechanism, severity and management for each pair, from a commercially licensed source — included with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check lamivudine, abacavir and dolutegravir against other medicinesHow interaction checks work

Lamivudine, abacavir and dolutegravir · interactions on record

2 records

2 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
Mechanism and what to do, in the interaction check
Interaction register. Grades as the source publishes them.

Same medicine, other countries

Lamivudine, abacavir and dolutegravir in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lamivudine, abacavir and dolutegravir products

Authorised across Europe · EMA

The same active substance is authorised in 5 EEA countries. Names it is sold under:

  • Iceland · Triumeq
  • Liechtenstein · Triumeq
  • Malta · Dolutegravir/Abacavir/Lamivudine Pharos
  • Norway · Triumeq
  • Portugal · Dolutegravir/Abacavir/Lamivudine Pharos

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ea728662-fcde-46aa-8c60-3faa23b2571c
GET /v1/drugs/ea728662-fcde-46aa-8c60-3faa23b2571c?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Dispergeerbare tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/triumeq-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Lamivudine, abacavir and dolutegravir",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp129443",
  "excipients": [
    "AARDBEIENCRÈMESMAAKSTOF PERMASEAL PHS-132963 Givaudan",
    "ACESULFAAM KALIUM (E 950)",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSPOVIDON (E 1202)",
    "IJZEROXIDE GEEL (E 172)",
    "MACROGOL",
    "MALTODEXTRINE",
    "MANNITOL (D-) (E 421)",
    "MAÏSZETMEEL, GEMODIFICEERD",
    "NATRIUMSTEARYLFUMARAAT",
    "NATRIUMZETMEELGLYCOLAAT",
    "POLYVINYLALCOHOL (E 1203)",
    "POVIDON K 30 (E 1201)",
    "PROPYLEENGLYCOL (E 1520)",
    "SILICIUMDIOXIDE (E 551)",
    "SUCRALOSE (E 955)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "ABACAVIRSULFAAT",
    "DOLUTEGRAVIR NATRIUM",
    "LAMIVUDINE 0-WATER"
  ],
  "leaflet_url": null,
  "authorised_at": "2023/02/20",
  "procedure_number": "EMEA/H/C/002754",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/14/940",
  "additional_monitoring": "N"
}
API referenceMCP serverPlans

See everything about lamivudine, abacavir and dolutegravir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console